Impedimed Ltd (IPD) - Total Assets
Based on the latest financial reports, Impedimed Ltd (IPD) holds total assets worth AU$38.36 Million AUD (≈ $27.14 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IPD book value for net asset value and shareholders' equity analysis.
Impedimed Ltd - Total Assets Trend (2006–2025)
This chart illustrates how Impedimed Ltd's total assets have evolved over time, based on quarterly financial data.
Impedimed Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Impedimed Ltd's total assets of AU$38.36 Million consist of 66.0% current assets and 34.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$21.68 Million | 53.3% |
| Accounts Receivable | AU$2.96 Million | 7.1% |
| Inventory | AU$861.00K | 2.1% |
| Property, Plant & Equipment | AU$883.00K | 2.1% |
| Intangible Assets | AU$10.19 Million | 24.5% |
| Goodwill | AU$2.78 Million | 6.7% |
Asset Composition Trend (2006–2025)
This chart illustrates how Impedimed Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Impedimed Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Impedimed Ltd's current assets represent 66.0% of total assets in 2025, an increase from 0.0% in 2006.
- Cash Position: Cash and equivalents constituted 53.3% of total assets in 2025, up from 0.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, a decrease from 91.0% in 2006.
- Asset Diversification: The largest asset category is cash and equivalents at 53.3% of total assets.
Impedimed Ltd Competitors by Total Assets
Key competitors of Impedimed Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Vitrolife AB
ST:VITR
|
Sweden | Skr11.12 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Tellgen Corp
SHE:300642
|
China | CN¥2.00 Billion |
|
Lumos Diagnostics Holdings Ltd
AU:LDX
|
Australia | AU$20.81 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
|
Ok Biotech Co Ltd
TW:4155
|
Taiwan | NT$3.89 Billion |
|
Promimic AB
ST:PRO
|
Sweden | Skr75.71 Million |
|
Memphasys Ltd
AU:MEM
|
Australia | AU$10.45 Million |
Impedimed Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.74 | 4.57 | 4.13 |
| Quick Ratio | 3.41 | 4.39 | 4.00 |
| Cash Ratio | 0.00 | 3.05 | 1.04 |
| Working Capital | AU$18.81 Million | AU$18.11 Million | AU$18.20 Million |
Impedimed Ltd - Advanced Valuation Insights
This section examines the relationship between Impedimed Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.62 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | -11.3% |
| Total Assets | AU$41.66 Million |
| Market Capitalization | $12.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Impedimed Ltd's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Impedimed Ltd's assets decreased by 11.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Impedimed Ltd (2006–2025)
The table below shows the annual total assets of Impedimed Ltd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$41.66 Million ≈ $29.48 Million |
-11.34% |
| 2024-06-30 | AU$46.99 Million ≈ $33.25 Million |
-31.64% |
| 2023-06-30 | AU$68.74 Million ≈ $48.64 Million |
+17.10% |
| 2022-06-30 | AU$58.70 Million ≈ $41.53 Million |
+71.61% |
| 2021-06-30 | AU$34.20 Million ≈ $24.20 Million |
+3.45% |
| 2020-06-30 | AU$33.06 Million ≈ $23.39 Million |
+46.42% |
| 2019-06-30 | AU$22.58 Million ≈ $15.98 Million |
-45.68% |
| 2018-06-30 | AU$41.57 Million ≈ $29.41 Million |
-35.39% |
| 2017-06-30 | AU$64.34 Million ≈ $45.53 Million |
-28.96% |
| 2016-06-30 | AU$90.57 Million ≈ $64.08 Million |
+138.86% |
| 2015-06-30 | AU$37.92 Million ≈ $26.83 Million |
+153.49% |
| 2014-06-30 | AU$14.96 Million ≈ $10.58 Million |
+26.08% |
| 2013-06-30 | AU$11.86 Million ≈ $8.39 Million |
-39.51% |
| 2012-06-30 | AU$19.61 Million ≈ $13.88 Million |
-13.99% |
| 2011-06-30 | AU$22.80 Million ≈ $16.14 Million |
-8.45% |
| 2010-06-30 | AU$24.91 Million ≈ $17.63 Million |
+90.18% |
| 2009-06-30 | AU$13.10 Million ≈ $9.27 Million |
-9.76% |
| 2008-06-30 | AU$14.52 Million ≈ $10.27 Million |
-33.38% |
| 2007-06-30 | AU$21.79 Million ≈ $15.42 Million |
+370.60% |
| 2006-06-30 | AU$4.63 Million ≈ $3.28 Million |
-- |
About Impedimed Ltd
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue compositi… Read more